Treatment-resistant schizophrenia

Treatment-resistant schizophrenia is a severe clinical subtype of schizophrenia affecting the central nervous system, characterized by persistent psychotic symptoms and substantial functional impairment despite standard pharmacotherapy

Treatment-resistant schizophrenia is a severe clinical subtype of schizophrenia affecting the central nervous system, characterized by persistent psychotic symptoms and substantial functional impairment despite standard pharmacotherapy Pathophysiologically, while typical schizophrenia often involves hyperdopaminergic signaling in the striatum, treatment-resistant disease is frequently associated with normodopaminergic function alongside prominent glutamatergic dysregulation, frontotemporal neuro...

It is clinically defined by the failure to achieve adequate symptom reduction following at least two separate, sequential trials of different antipsychotic medications administered at therapeutic doses for an adequate duration, with confirmed adherence

It is clinically defined by the failure to achieve adequate symptom reduction following at least two separate, sequential trials of different antipsychotic medications administered at therapeutic doses for an adequate duration, with confirmed adherence

It is clinically defined by the failure to achieve adequate symptom reduction following at least two separate, sequential trials of different antipsychotic medications administered at therapeutic doses for an adequate duration, with confirmed adherence

Pathophysiologically, while typical schizophrenia often involves hyperdopaminergic signaling in the striatum, treatment-resistant disease is frequently associated with normodopaminergic function alongside prominent glutamatergic dysregulation, frontotemporal neurostructural alterations, and progressive cortical atrophy

Pathophysiologically, while typical schizophrenia often involves hyperdopaminergic signaling in the striatum, treatment-resistant disease is frequently associated with normodopaminergic function alongside prominent glutamatergic dysregulation, frontotemporal neurostructural alterations, and progressive cortical atrophy